Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Equities researchers at Zacks Research increased their Q3 2026 earnings estimates for Agios Pharmaceuticals in a research report issued to clients and investors on Thursday, August 20th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings per share of ($1.79) for the quarter, up from their previous estimate of ($1.85). The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($5.80) per share. Zacks Research also issued estimates for Agios Pharmaceuticals' Q4 2026 earnings at ($1.77) EPS, FY2026 earnings at ($6.94) EPS, Q3 2027 earnings at ($1.51) EPS, Q4 2027 earnings at ($1.44) EPS, Q1 2028 earnings at ($1.23) EPS, Q2 2028 earnings at ($1.05) EPS and FY2028 earnings at ($3.88) EPS.
A number of other equities analysts also recently commented on AGIO. Royal Bank Of Canada lifted their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a "sector perform" rating in a report on Tuesday, July 7th. HC Wainwright raised their price target on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Bank of America lifted their price target on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 7th. Truist Financial lowered their price objective on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a "buy" rating for the company in a research report on Friday, July 31st. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Agios Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $41.25.
Read Our Latest Stock Analysis on AGIO
Agios Pharmaceuticals Stock Performance
Shares of NASDAQ AGIO opened at $33.09 on Monday. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of -4.72 and a beta of 0.58. Agios Pharmaceuticals has a twelve month low of $22.24 and a twelve month high of $46.00. The business has a 50 day simple moving average of $35.84 and a 200-day simple moving average of $31.43.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The firm had revenue of $44.75 million during the quarter, compared to the consensus estimate of $26.39 million.
Insider Transactions at Agios Pharmaceuticals
In related news, insider Sarah Gheuens sold 30,000 shares of the company's stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total transaction of $914,400.00. Following the completion of the transaction, the insider directly owned 54,645 shares in the company, valued at $1,665,579.60. This represents a 35.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Agios Pharmaceuticals
Several hedge funds and other institutional investors have recently modified their holdings of AGIO. BlackRock Inc. acquired a new stake in shares of Agios Pharmaceuticals in the second quarter valued at approximately $239,582,000. Wellington Management Group LLP boosted its position in shares of Agios Pharmaceuticals by 485.5% during the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company's stock worth $99,203,000 after buying an additional 2,049,287 shares during the period. MPM Bioimpact LLC acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $35,478,000. ADAR1 Capital Management LLC bought a new position in Agios Pharmaceuticals in the 2nd quarter worth approximately $47,800,000. Finally, State Street Corp grew its holdings in Agios Pharmaceuticals by 37.4% in the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company's stock worth $84,604,000 after buying an additional 845,433 shares in the last quarter.
About Agios Pharmaceuticals
(
Get Free Report)
Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.
Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
